IVA

Inventiva Sa

IVA, USA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

https://inventivapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IVA
stock
IVA

Inventiva (NASDAQ:IVA) Trading 4.8% Higher - Time to Buy? MarketBeat

Read more →
IVA
stock
IVA

Inventiva drops 35% in a month after InvestingPro’s overvalued warning By Investing.com Investing.com Australia

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

Target Price:

$15.875

Analyst Picks

Strong Buy

6

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-51.94

Low 1

High 3

Return on Equity (ROE)

-

Very High

1,881.90 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-98.52 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,211.27 %

Low 5%

High 15%

Investors

* Institutions hold a combined 3.55% of the total shares of Inventiva Sa

1.

Yiheng Capital LLC

(1.902%)

since

2025/06/30

2.

NEA Management Company, LLC

(1.0518%)

since

2025/06/30

3.

Bvf Inc

(0.4933%)

since

2025/06/30

4.

Commonwealth Equity Services Inc

(0.0391%)

since

2025/06/30

5.

UBS Group AG

(0.0197%)

since

2025/06/30

6.

Citadel Advisors Llc

(0.0168%)

since

2025/06/30

8.

Creative Planning Inc

(0.0072%)

since

2025/06/30

9.

Fidelity Nasdaq Composite Index

(0.0034%)

since

2025/07/31

10.

Morgan Stanley - Brokerage Accounts

(0.0015%)

since

2025/06/30

11.

Covestor Ltd

(0.0003%)

since

2025/06/30

12.

Atlantic Union Bankshares Corp

(0.0002%)

since

2025/06/30

13.

BNP Paribas Arbitrage, SA

(0.0001%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-0.29

EPS Difference

0.29

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.